Allotransplantation

BioStem Technologies Announces Partnership with Kill Cliff FC

Retrieved on: 
Wednesday, December 14, 2022
Public sector banks in India, Physician, Champion, Allotransplantation, MMA, Health, FDA, Regenerative medicine, OTC, Injury, Ultimate, Erosion (morphology), Research, American Association of Tissue Banks, Athlete, COVID-19, AATB, Pharmaceutical industry

POMPANO BEACH, FLORIDA., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, is pleased to announce that the Company will be a corporate sponsor of Kill Cliff Fight Club (“Kill Cliff FC”), a world-renowned MMA training center based-in Southern Florida.

Key Points: 
  • Kill Cliff FC has more than 80 professional fighters including current and former Champions from the Ultimate Fighting Championship (“UFC”), Bellator MMA, One Championship, and other elite MMA promotions.
  • Under Henri Hooft and Greg Jones, Kill Cliff FC has developed and produced elite fighters such as Michael Chandler, Gilbert Burns, Robbie Lawler, Logan Storley, Aung La Nsang and Gregory Rodrigues.
  • Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “The entire team at BioStem is excited for our products to become an integral part of the MMA community.
  • Now BioStem will be associated with some of the biggest moments in MMA.”
    Greg Jones, Co-Founder of Kill Cliff FC, commented “Kill Cliff FC is truly honored to be partnering with BioStem.

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

Retrieved on: 
Monday, December 12, 2022
TRAC, RNA, Western literature, Rachel Haurwitz, Patient, Fast Track, Clinical trial, Annual report, Medicine, CST, CAR, Security (finance), FDA, University of California, Food, Safety, DNA, Phenotype, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Next, PD-1, Allotransplantation, ASH, Infrared spectroscopy correlation table, Spectrochimica Acta Part B, Risk, CR, Reindeer, Alveolar soft part sarcoma, Multicenter Automatic Defibrillator Implantation Trial, Orphan drug, CRISPR/Cpf1, Research, CRISPR, Genome, Lymphatic system, University, Vaccine, Pharmaceutical industry

BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells). Cohort 1 results show:

Key Points: 
  • Today at the 64th Annual ASH meeting, a trial-in-progress poster is being presented to provide details of the design and objectives of the ANTLER Phase 1 trial for CB-010 in r/r B-NHL.
  • Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
  • “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
  • Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Neoplasm, NK, Lentivirus, HIP, Exposition, ASH, Biotechnology, CD47, MHC, Gene, Research, COVID-19, Intrinsic and extrinsic properties, CD22, CAR, Macrophage, Lymphoma, Specific, Cancer, Risk, Drug development, Immunosuppression, Society, CRISPR, Multiple myeloma, Animal, Immune system, BCMA, Social disruption, Tissue, Patient, SANA, Cell, Leukemia, ECD, Poster, Allotransplantation, CD19, Ability, IND, Therapy, Vaccine

SEATTLE, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, shared data in six presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Saturday, December 10 to Tuesday, December 13, 2022 in New Orleans, LA, which highlighted further progress with key technologies supporting Sana’s ex vivo allogeneic CAR T cell programs and in vivo platform.

Key Points: 
  • The challenge for the field to date in generating immune cloaked cells has been turning off both the adaptive and innate immune system concurrently.
  • The company has presented data across multiple preclinical models highlighting the potential of this platform to cloak cells from immune recognition.
  • These data indicate that this scaled manufacturing process can produce fully engineered HIP-modified CD19-targeted allogeneic CAR T cells with high editing efficiency and specificity.
  • The company expects to study SG295, an in vivo CAR T with CD8-targeted fusosome delivery of a CD19-targeted CAR, in patients with B cell malignancies.

Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Retrieved on: 
Saturday, December 10, 2022
Infrastructure as code, Cell, Patient, PRIME, Baylor College of Medicine, Lymphatic system, Neoplasm, Hodgkin lymphoma, Center for Cell and Gene Therapy, FDA, Marketing, Safety, Cancer, Allotransplantation, TT11, Epstein–Barr virus, Toxic epidermal necrolysis, Trial of the century, ASH, CD30, European Medicines Agency, Hematological Cancer Research Investment and Education Act, Graft-versus-host disease, CHL, Baylor University, Gene therapy, Immune system, Society, GVHD, Therapy, Risk, Pharmaceutical industry, Doctor of Philosophy

SINGAPORE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced enhanced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy being co-developed by Baylor College of Medicine and Tessa. The results, detailed in an oral podium presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) on December 10, demonstrated TT11X to be well-tolerated at all dosing levels, eliciting a 79% overall response rate and complete disappearance of tumor in six patients.

Key Points: 
  • An overall response rate of 79% (11/14 patients) was observed across all three dose levels, including six complete responses and six partial responses.
  • The strongest responses were achieved in patients treated at the higher dose levels with additional infusions resulting in increasing effectiveness.
  • “Importantly, CD30.CAR EBVSTs elicited a clinical response in 11 of 14 patients with advanced CD30-positve Hodgkin lymphoma including six complete responses.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics

Retrieved on: 
Thursday, December 8, 2022
Newton, Annual report, Physician, Allotransplantation, Wound, Security (finance), FDA, Infection, Skin, Burn, Health, Risk, Research, Sterilization, Osteoarthritis, Therapy, Patient, Risk management, Medical imaging, Pharmaceutical industry

MARIETTA, Ga., Dec. 08, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion®, for the development of future biologic products focused on wound and surgical recovery applications.

Key Points: 
  • “Today’s transaction enables a meaningful expansion of our product development pipeline ambitions,” stated Todd Newton, MIMEDX interim Chief Executive Officer.
  • MIMEDX expects this technology to be included in the creation of a number of new antimicrobial biologic products for the Wound & Surgical markets.
  • Under the terms of the agreement, MIMEDX has exclusive rights to develop future products for the wound care, burn, and surgical fields using Turn’s IP.
  • Turn Therapeutics is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care.

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Royal College of Pathologists, NK, Glucose, Immunotherapy, Fibroblast, Nottingham Trent University, Society, TME, Patient, Cancer, Allotransplantation, CIML, Cell, Cryopreservation, Tumor microenvironment, Bone marrow, AML, Safety, Acute myeloid leukemia, Natural killer T cell, FRSB, ASH, Acute leukemia, Phenotype, Pharmaceutical industry, Vaccine, Medical imaging, Fine chemical

These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML.

Key Points: 
  • These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML.
  • Further, the identification of a TME immune signature highly predictive of response may be an impactful tool to support future clinical studies.
  • These data further validate our approach deploying WU-NK-101 for AML, said Jan Davidson-Moncada, M.D., Ph.D., Chief Medical Officer of Wugen.
  • In early clinical studies, memory NK cells have already demonstrated impressive efficacy against AML.

Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

Retrieved on: 
Thursday, December 15, 2022
Faculty, University of Southern California, NKT, International Society, Association of American Physicians, Harvard University, Society, Hematology, Patient, Science, TCR, Cancer, Allotransplantation, California Institute of Technology, Doris Duke, Research, Biomedical engineering, Biology, Knowledge, Stanford University, Division, Stem cell, Medicine, Chemical engineering, Health, Haematopoietic system, Developmental Biology (journal), Multimedia, Coronavirus Scientific Advisory Board (Turkey), CAR, USC, University, Physician, Engineering, Regenerative medicine, ACUA, Berkeley, Vaccine, Dentistry, Pharmaceutical industry, Blood

LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.
  • Dr. Negrin is one of the world's leading experts in hematology and cellular immunology and joins Appia Bio's scientific founders in advising the Company's research and development.
  • "We are thrilled to have Dr. Negrin join our world-class Appia Bio Scientific Advisory Board.
  • Dr. Negrin joins Appia Bio's Scientific Advisory Board and Scientific Founders in advising the company, comprised of the following leaders in immunology, immuno-oncology, and cell therapy engineering:
    Irving Weissman, M.D., director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia & D.K.

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Retrieved on: 
Tuesday, December 6, 2022
Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Stem cell, Therapy, Security (finance), III, Literature, Heart, MSC, Food, IND, Union, Doctor of Philosophy, Patient, NK1R, Heart failure, Allotransplantation, FDA, Incidence, Substance P, Cell, BCDA, Safety, Tachykinin receptor, Inflammation, Food and Drug Administration, Pharmaceutical industry

We intend to provide a complete cell therapy solution for ischemic heart failure patients that encompasses both autologous and off the shelf allogeneic cell therapies.

Key Points: 
  • We intend to provide a complete cell therapy solution for ischemic heart failure patients that encompasses both autologous and off the shelf allogeneic cell therapies.
  • Allogeneic NK1R+ MSC are culture-expanded, bone marrow-derived, mesenchymal stem cells that are Neurokinin 1 receptor positive.
  • The BioCardia cell therapy consists of cells from younger, extensively prescreened donors that are expanded to provide multiple dosage forms from a single donor.
  • BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call

Retrieved on: 
Tuesday, November 15, 2022
COVID-19, OTC, Allotransplantation, Public sector banks in India, Regenerative medicine, Physician, Webcast, Research, AATB, American Association of Tissue Banks, FDA, Risk management

About BioStem Technologies, Inc. (OTC PINK: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.

Key Points: 
  • About BioStem Technologies, Inc. (OTC PINK: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
  • The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method.
  • BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB").
  • Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.